



Large multinodular goitre — outpatient radioiodine treatment

Wole guzowate olbrzymie — ambulatoryjne leczenie radiojodem

Sonia Kaniuka-Jakubowska¹, Anna Lewczuk¹, Krystyna Mizan-Gross², Maciej Piskunowicz³, Adam Zapaśnik³, Piotr Lass², Krzysztof Sworczak¹

¹Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland

²Department of Nuclear Medicine, Medical University of Gdansk, Gdansk, Poland

³Department of Radiology, Medical University of Gdansk, Gdansk, Poland

Abstract

Introduction: 131-I treatment of nodular, especially nontoxic, goitre is still reserved mainly for elderly patients, whose numerous concomitant diseases disqualify them from surgery. Therapy often involves isolation and is available only in selected centres, which may be located far from some patients' places of residence, which is inconvenient for elderly people.

The aim of the study was to assess the effectiveness of outpatient fractionated 131-I treatment of patients with large nodular goitres, as well as to evaluate complications and the factors affecting treatment results.

Material and methods: The study included 35 patients with a large nodular goitre. Thyroid volume and treatment results were evaluated using US and CT neck examination.

Results: Mean thyroid volume prior to treatment was 104.36 mL (range 36.23–301.09 mL). An average administered 131-I activity was 1806 MBq (range 800–4000). The average reduction of goitre volume was 43.18% (range –17.23–89.66%). Final treatment results correlated with the thyroid size reduction obtained three months after treatment ($r = 0.74$; $p = 0.001$). Symptoms of transient hyperthyroidism were observed in 8.57% of patients, in 5.4% Graves disease was induced (including severe Graves' orbitopathy in 2.7%), and in 2.86% TRAb increase without development of hyperthyroidism was observed. The treatment results were not influenced by initial thyroid volume ($r = -0.01$; $p = 0.95$). An increase in thyroid volume during the treatment was reported in 20% of patients, with a mean increase of 22.3% (range 0.63–55.03%). Post-treatment hypothyroidism was diagnosed in 42.9% of patients. One patient was diagnosed with salivary gland damage.

Conclusions: Fractionated 131-I treatment of large nodular goitres is an effective method, the results of which are comparable to those obtained from the administration of one-time high doses of radioiodine. (*Endokrynol Pol* 2015; 66 (4): 301–307)

Key words: radioiodine; radioiodine treatment; goitre; nontoxic goitre

Streszczenie

Wstęp: Leczenie 131-I wola guzowatego olbrzymiego, szczególnie obojętnego, nadal zarezerwowane jest głównie dla pacjentów w starszym wieku, z licznymi chorobami towarzyszącymi dyskwalifikującymi ich z leczenia zabiegowego. Terapia, szczególnie w przypadku dużych rozmiarów wola wiąże się z izolacją po podaniu 131-I, a leczenie jest możliwe tylko w wybranych ośrodkach często oddalonych od miejsca zamieszkania, co jest utrudnieniem dla osób starszych.

Celem pracy była ocena skuteczności leczenia wola olbrzymiego 131-I w warunkach ambulatoryjnych dawkami frakcjonowanymi z analizą czynników wpływających na efekt terapii oraz oceną jej powikłań.

Materiały i metody: Analizą objęto 35 osób z wolem guzowatym olbrzymim. Ocenę objętości tarczycy i efektów leczenia wykonano z użyciem badań USG oraz CT szyi.

Wyniki: Średnia objętość wola przed leczeniem wynosiła 104,36 mL (zakres 36,23–301,09), a średnia podana aktywność 131-I to 1806 MBq (zakres 800–4000). Uzyskano redukcję objętości wola średnio o 43,18% (zakres –17,23–89,66%). Ostateczny efekt leczenia korelował z poziomem redukcji uzyskanym po 3 miesiącach leczenia ($r = 0,74$; $p = 0,0010$). Efekt leczenia nie zależał od wyjściowej wielkości wola ($r = -0,01$; $p = 0,95$). Objawy przejściowej nadczynności tarczycy obserwowano u 8,57% leczonych, u 5,4% wyindukowano chorobę Gravesa-Basedowa (u 2,7% ciężką orbitopatię) u 2,86% zaobserwowano wzrost miana przeciwciał przeciw receptorowi TSH bez objawów nadczynności tarczycy. Przejściowo powiększenie tarczycy w trakcie leczenia obserwowano u 20% leczonych, a objętość gruczołu wzrosła średnio o 22,3% (zakres 0,63–55,03). Niedoczynność tarczycy po zakończeniu leczenia stwierdzono u 42,9% pacjentów. W jednym przypadku obserwowano, nieopisywane wcześniej po stosowaniu małych dawek 131-I, popromienne uszkodzenie ślinianek.

Wnioski: Leczenie wola guzowatego olbrzymiego frakcjonowanymi dawkami 131-I jest leczeniem skutecznym, o efektach porównywalnych do stosowania dużych jednorazowych dawek radiojodu. (*Endokrynol Pol* 2015; 66 (4): 301–307)

Słowa kluczowe: radiojod; jod radioaktywny; leczenie radiojodem; wole obojętne; wole olbrzymie

This work was supported by the National Science Centre (NCN) from funds for science in 2009-2013 as research project number N N402 477137.



Sonia Kaniuka-Jakubowska M.D., Ph.D., Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Debinki St. 7, 80-952 Gdańsk, Poland; phone: +48 58 349 28 40, fax: +48 58 349 28 41, e-mail: sonia.kaniuka@gumed.edu.pl

Introduction

Over the last two decades radioiodine treatment of toxic and nontoxic nodular goitres has gained considerable popularity. However, surgery still remains the preferred method. In toxic goitre one of the options is antithyroid drug treatment. Nevertheless, it cannot be used permanently due to its negative impact on the thyroid volume, causing further goitre growth [1, 2]. 131-I treatment, especially in nontoxic goitre, has thus far been reserved mainly for elderly patients, whose numerous concomitant diseases disqualify them from surgery [3, 4]. Without hyperthyroidism-related symptoms, patients with long-standing nontoxic nodular goitres and those on antithyroid drug therapy are not willing to undergo any other treatment, even relatively non-invasive 131-I administration, especially when it involves post-treatment isolation. The administration of rhTSH shortens the hospitalisation period, yet in many countries no reimbursement is given for rhTSH nodular goitre treatment [5, 6]. Moreover, this method is available only in selected centres that offer hospitalisation. The centres are often located a considerable distance from elderly patients' place of residence, which causes great inconvenience to them.

The aim of the study was to assess the effectiveness of outpatient fractionated 131-I treatment of patients with large nodular goitres, with evaluation of the treatment complications and the factors affecting treatment results.

Material and methods

The study included 37 patients with nodular goitres (25 euthyroid, 10 with subclinical hyperthyroidism), who did not give their consent to surgical treatment, were disqualified from surgery due to their concomitant diseases, or were diagnosed with post-surgical goitre regrowth. The study was conducted in the Department of Endocrinology and Internal Medicine and the Outpatient Endocrinology Clinic of the Medical University of Gdansk (MUG) between 2009 and 2012. The treatment was conducted in the Department of Nuclear Medicine of the same University. The scheme of the study and treatment was approved by the MUG Independent Bioethics Commission. During the study, two patients were excluded from evaluation after they were diagnosed with radioiodine-induced Graves disease, and in one of them symptoms of severe Graves orbitopathy were observed. Prior to the treatment, the patient did not show any symptoms of Graves hyperthyroidism, she had negative TRAb, and she was a smoker.

Table I. Basic characteristics of the study group

Tabela I. Charakterystyka podstawowa badanej grupy

Study group N=35		
Age (years)	median (range)	65.63 (49.00–84.00)
Duration of symptoms (years)	median (range)	15.83 (1.00–50.00)
L-T4 dosage [$\mu\text{g}/\text{day}$]	median (range)	9.23 (0–75.0)
Previous L-T4 therapy	N (%)	6 (17.1%)
Previous strumectomy	N (%)	6 (17.1%)
Family history	N (%)	13 (37.1%)
Smokers	N (%)	17 (48.6%)
Pressure on or dislocation of trachea	N (%)	21 (60.0%)
Substernal goitre	N (%)	17 (48.6%)
Euthyroid	N (%)	25 (71.4%)

The final group consisted of 35 patients (33 women, 2 men) with large nodular goitre, who were administered 131-I. The characteristics of the patient group is shown in Table I.

131-I treatment

Radioiodine was administered orally, with an activity of 800 MBq per capsule. The radioiodine activity was determined using modified Marinelli's formula [7]:

$$A = (C \times V \times 100)/U$$

A — administered 131-I activity [MBq]; C — constant, usually between 3 and 5 [MBq/g of thyroid tissue], in the study the assumed value was 4.44 MBq/g; V — thyroid mass [g] (based on US study); U — thyroid 131-I uptake (RAIU) 24 hours after 131-I administration (%).

The calculated 131-I activity was fractionated, with a single administered activity of 800 MBq. In the case of calculated activities < 800 MBq a full dose (800 MBq) was administered. In the case of calculated activities > 800 MBq, 800 MBq was administered in repeated doses. In order to avoid the "thyroid stunning" effect, consecutive radioiodine doses were administered every three months.

Imaging evaluation

US examinations were performed in all patients prior to treatment, as well as 3, 6, and 12 months afterwards. All measurements were taken by the same radiologist using a SIEMENS S2000 (Siemens, Erlangen, Germany) with a 18L6 HD linear transducer (5.5–18 MHz) and 6C2 convex transducer 6C2 (2–6 MHz).

The US estimation of thyroid volume was based on the ellipsoid formula, adding the volumes of both lobes measured using the following formula [8]:

$$V = H \cdot W \cdot D \cdot \frac{\pi}{6}$$

where:

H — height [cm], W — width [cm], D — depth [cm]

All patients with suspicion of malignancy in US additionally underwent FNAB (fine needle aspiration biopsy).

CT thyroid assessment without contrast enhancement was conducted both before and 12 months after the treatment. All examinations were performed with the same GE LightSpeed 32-Slice CT Scanner (GE Healthcare Technologies, Wisconsin, USA) by using the spiral technique. Images were taken in sequences every 5 mm. Thyroid volume was calculated planimetrically using Siemens SYNGO.VIA software.

Evaluation of hormonal function of the gland

Serum concentration of TSH (reference values: 0.35–4.94 μ IU/mL), fT4 (reference values: 9.01–19.05 pmol/L), and fT3 (reference values: 2.63–5.7 pmol/L) as well as anti-TPO and anti-TG antibodies (negative < 150 IU/mL and < 4.11 IU/mL, respectively) were measured by immunoassay using an ARCHITECT analyser (Abbott Laboratories, USA). Thyrotropin receptor antibodies (TRAb) antibodies (negative < 1.8 IU/L) were measured by ELISA assay using a EUROIMMUN analyser.

Statistical analysis

Statistical calculations were performed using the StatSoft, Inc. (2011) STATISTICA data analysis software system, version 10.0. (www.statsoft.com) and MS Excel spread sheets. The significance of differences between the two groups was evaluated using tests of statistical significance: Student's *t*-test or the Mann-Whitney U test. The significance of differences between more than two groups was tested using the F-test (ANOVA) or Kruskal-Wallis one-way analysis of variance. In the case of statistically significant differences between the groups, post hoc tests were used (the Tukey range test for the F-test and the Dunn test for Kruskal-Wallis test). In the case of two related variables model, the Student's *t*-test or Wilcoxon signed-rank test were used. The significance of differences between more than two variables in the related variables model was determined with repeated measures analysis of variance or the Friedman test.

In order to determine the interdependence, strength, and direction between the variables, a correlation analysis was used to calculate Pearson correlation coefficients. In all calculations the assumed level of significance was set at $\alpha = 0.05$.




Figure 1. Correlation between reduction level 3 months after the treatment and total reduction level

Rycina 1. Korelacja stopnia redukcji objętości tarczycy po 3 miesiącach po leczeniu z całkowitym stopniem redukcji

Results

Mean thyroid volume in US was 104.36 mL (range: 36.23–301.09 mL, median: 92.04 mL), and in CT 112.09 mL (range: 35.75–315.97 mL, median: 91.07 mL). No statistically significant difference was observed between US and CT volumetric evaluation either before the treatment ($H = 1.74$; $p = 0.6291$) or afterwards ($H = 1.09$; $p = 0.7786$). Additionally, using Bland-Atman plots, we assessed previously that in volumetric thyroid measurements US is a comparable method to CT; therefore, in this study US examination was established as a reference method [9].

The lowest total activity administered was 800 MBq and 4000 MBq was the highest. On average, 1806 MBq was administered. All patients were administered activities higher or equal to the calculated activity. The mean absorbed activity calculated on the basis of goitre size, and iodine uptake by the thyroid was 6.16 MBq/g (range: 4.51–9.94 MBq/g of thyroid tissue).

Mean goitre size reduction reported in US examination was 43.18% (range: –17.23–89.66%, median: 47.02%). In only one patient an increase in thyroid volume was observed after the treatment. In absolute values, mean thyroid volume after the treatment was 58.66 mL (range: 10.82–203.32 mL, median: 53.20 mL) and differed significantly from the pre-treatment value ($t = 7.50$; $p = 0.0001$).

The evaluation of total goitre reduction with time proved to be the best treatment results achieved a year after the treatment. The volume reduction changed significantly with time (Friedman ANOVA: 30.40; $p = 0.0001$). The greatest decrease in goitre size (relative reduction) was observed during the first three months

after the treatment. The reduction of goitre size between 3 and 6 months after the treatment, similarly to the relative reduction between 6 and 12 months after the treatment, was significantly lower than the reduction reported during the first 3 months after the treatment (ANOVA $F = 8.47$; $p = 0.0005$).

The goitre reduction level obtained 3 months after the treatment correlates with the level obtained at the end of observation (correlation coefficient: 0.74; $p = 0.0010$) (Fig. 1).

Factors modifying the treatment efficacy were not determined. There was no correlation between goitre reduction and age ($r = -0.28$; $p = 0.1049$), L-T4 dosage ($r = 0.19$; $p = 0.2859$), pretreatment TSH level ($r = 0.09$; $p = 0.6030$), Iodine uptake ($r = -0.13$; $p = 0.4587$), total administered 131-I activity ($r = 0.14$; $p = 0.4130$), absorbed 131-I activity ($r = 0.14$; $p = 0.3965$), goitre duration ($r = -0.27$; $p = 0.1170$), and goitre size before treatment ($r = -0.01$; $p = 0.9542$). No differences in level of thyroid reduction were observed between patients with positive and negative anti-TPO and anti-TG antibodies ($t = 0.44$; $p = 0.6625$ and $t = 0.07$; $p = 0.9423$, respectively).

Prior to treatment 25 patients (71.4%) were euthyroid and the remaining 10 (28.6%) were diagnosed with subclinical hyperthyroidism. After the treatment 20 patients (57.1%) remained euthyroid and 15 (42.9%) required L-T4 substitution due to hypothyroidism. Symptoms of transient hyperthyroidism were observed in 3 patients, and in 2 patients Graves disease was induced. The latter two were excluded from the study, yet initially they accounted for 5.4 % of the whole group.

In 2 patients thyroid enlargement was reported 3 months after the completed treatment, with their thyroids increased in volume by 18.42 % and 2.57 %, respectively. In both cases final goitre reduction was eventually observed. US examination during the treatment (between consecutive 131-I administrations) revealed an increased thyroid volume in 7 patients. On average, thyroid increased by 22.3% (range 0.63–55.03%; median 19.58%). In none of the patients increased dyspnoea, stridor, or pressure sensation were observed.

Post-treatment hypothyroidism was reported in 15 patients (42.9%). Patients from this group had initially higher TSH and lower fT4 values than those who remained euthyroid after the treatment ($U = 28.00$; $p = 0.0001$ and $t = -3.84$; $p = 0.0005$). No correlation was observed between anti-TPO, anti-TG, and TRAb antibodies and the risk of post-treatment hypothyroidism. The evaluation of the other evaluated parameters did not reveal a higher risk of hypothyroidism. There was no difference in goitre size ($U = 93.00$; $p = 0.0597$), age ($U = 100.00$; $p = 0.0989$), iodine uptake ($U = 83.00$; $p = 0.1297$), total administered 131-I activity ($t = -0.68$;

$p = 0.4982$), goitre duration ($U = 122.50$; $p = 0.3681$), and absorbed 131-I activity ($t = 1.74$; $p = 0.0919$) between euthyroid and hypothyroid groups.

The number of anti-TPO and anti-TG positive patients significantly increased after treatment (anti-TPO 12 [34.29%] before *vs.* 15 [42.86%] after treatment $p = 0.0001$, anti-TG 14 [40.00%] before *vs.* 24 [68.57%] after treatment $p = 0.001$). Before treatment, 6 patients (17.14%) had elevated TRAb without clinical and laboratory features of hyperthyroidism. After treatment only 1 person (3.03%), different from those above, presented positive TRAb results. The low percentage of positive results does not allow us to discuss the significance of these changes.

Discussion

Surgery still remains the gold standard of nodular, especially nontoxic, goitre treatment. It is undoubtedly the method of choice for young patients without any concomitant diseases. In patients with a toxic goitre antithyroid drug treatment resolves metabolic problems, but still does not influence thyroid reduction; on the contrary it stimulates further goitre growth [1]. Apart from those patients who give their consent to surgery and do not have any contraindications, there are also those who need treatment but definitely should not be operated on. This group consists of elderly patients with numerous contraindications and those unwilling to give their consent to surgery. Assuming low goitre growth ratio (on average 10–20% per year), in patients with small goitre and in advanced age, observation and monitoring or, in some cases, antithyroid drug treatment may be sufficient [10]. The need for more invasive therapy starts when cosmetic aspects and symptoms including the compression of the trachea or other structures within the neck appear [11]. In this characterised group the method of choice, in other words the method when there is no alternative because surgical treatment is impossible, remains radioiodine treatment.

Radioiodine treatment allows a goitre reduction of 40–60% within 1–2 years after isotope administration [3, 12–14]. The range of thyroid volume reduction is comparable regardless of whether it is diffuse toxic [15], autonomous solitary toxic thyroid adenoma [16], or diffuse nontoxic [17, 18] and nontoxic multinodular goitre [2]. In EU countries (the United Kingdom, France, Belgium, the Netherlands, and Poland) the maximum radioiodine activity allowed in outpatient treatment is 370–800 MBq [19]. The used 131-I activity is determined by the 131-I uptake and goitre volume. Our study group consisted of elderly patients with long-standing, usually very large goitres, who required the administration of high radioiodine activities. In order to avoid inconvenient isolation and hospitalisation, a high dose of 131-I was fractionated to

activities allowed in outpatient treatment. The administration of lower ¹³¹I activities enables the therapy to be conducted in every centre that uses isotopes. It allows elderly patients to avoid hospital treatment that is available only in selected centres, often located a considerable distance from their place of residence. It seems to be of great importance, especially as the patients often suffer from numerous concomitant diseases, which somehow immobilise them.

In our study, using repeated ¹³¹I doses in outpatient treatment of large nodular goitre, we reported a goitre reduction of approximately 43% a year after the treatment. The outcome did not differ from the results of the studies in which high, single doses were used [3, 14, 20–22].

The results improved with time and were highest a year after the treatment. Studies with a longer observation period report increased goitre reduction in time from 38% during the first year to 44% after 2 years of observation and from 34% to 55%, respectively [12, 22]. The authors of the studies with a longer follow-up report as much as a 71.9% reduction [21]. Verelst et al. observed the best results after less than a year of treatment with a nearly maximum effect 24 to 30 months after the therapy [23]. Similarly to what Nygaard et al. reported in toxic goitre, we observed the greatest decrease in goitre volume within the first 3 months after the treatment, with a subsequent decrease in reduction degree [2].

An interrelationship never described before but observed in our study is the correlation between the final treatment results and the preliminary results obtained 3 months after the treatment. We found that the results obtained a short time after the treatment can provide a reliable bias for predicting final results. This information may be of great clinical importance, when making a decision regarding the continuation of treatment and the administration of the next ¹³¹I dose.

The dependence of treatment results on the other parameters still remains an unresolved issue. According to Le Moli et al., treatment results depend on the administered ¹³¹I activity [24]. In our study, however, we did not observe any correlation between the administered ¹³¹I activity and the treatment results. Similarly to us, despite using a complicated algorithm to calculate ¹³¹I activity, Bonnema et al. did not show any relation between the administered ¹³¹I activity and the obtained results [20]. Jarlov et al. questioned the sense of precise ¹³¹I activity calculation. Comparing the effects of ¹³¹I toxic goitre treatment in the administration of a fixed dose, based on gland size assessment by palpation only, to the precise calculation of the activity based on the morphology of the gland, iodine uptake, and US estimation of goitre size, they did not observe any differences [25]. Analysing the interdependence

between the initial goitre size and treatment results, we did not find any correlation. Based on the publications by Danish researchers, we expected treatment results to decrease with the increase in initial goitre volume [22, 24]. Le Moli et al. showed a correlation of treatment results with goitre duration and patient's age as indirect factors determining the goitre size [24]. In our study, we neither observed a correlation between thyroid volume and treatment results nor a correlation between the treatment results and duration of the disease or the age of the patients. Moreover, we did not find a correlation between the L-T4 dosage administered before the treatment, the hormonal function before surgery, iodine uptake, smoking, positive anti-TG, and anti-TPO antibodies and thyroid volume reduction. Given the obtained results, based on our work, the reason for the observed discrepancies in thyroid volume reduction, ranging from a 17.23% goitre growth to an 89.66% goitre reduction, remains unexplained.

Similarly to Le Moli et al., we did not observe any longer the cases of subclinical hyperthyroidism after the treatment [24]. In the study, after ¹³¹I treatment 42.9% of the patients required L-T4 substitution, including those with initial post-strumectomy hypothyroidism. Considering TSH as a goitre growth factor, we initiated L-T4 treatment in all patients whose TSH level exceeded 4 μ IU/mL, as did Wesche et al. [22]. All patients submitted to L-T4 therapy were classified as hypothyroid, with a possibly overestimated percentage of hypothyroidism cases reported in the study. Post-treatment hypothyroidism risk factors were not determined. We established that the administered ¹³¹I activity did not affect the risk of hypothyroidism, and neither did the thyroid volume, patient's age, iodine uptake, goitre duration, or anti-TPO and anti-TG antibodies. We observed that patients with hypothyroidism after the treatment initially had higher TSH and lower fT4 levels. These results confirm the conclusions drawn by Wesche et al. that subclinical hyperthyroidism is a protective factor against hypothyroidism after ¹³¹I treatment [26].

An early complication following ¹³¹I treatment is transient thyrotoxicosis resulting from thyroid cell damage. In the available literature, the incidence of this complication is estimated at between 0% and 28% [13, 17, 22, 24]. In our study, 8.57% of the patients were diagnosed with hyperthyroidism caused by transient, self-limiting form of thyroiditis. This complication had no clinical implications. However, such risk cannot be excluded, especially in patients with heart rhythm disturbances and heart failure, in whom even transient thyrotoxicosis may significantly deteriorate their condition. In 2 patients the treatment induced autoimmune thyroiditis. In the whole group, the risk of this complication was estimated to be 5.41%. Nygaard et al. presented

similar results (5%) of Graves-like hyperthyroidism incidence after the 131-I treatment in a retrospective study of 191 patients with a nontoxic goitre [27]. Apart from ours, to the authors' best knowledge, there is only one case study that describes GO induction after 131-I treatment of nontoxic goitre [28]. Clinically, at the time of 131-I administration the patient did not show any symptoms of Graves hyperthyroidism or GO. She was a smoker, which theoretically increased the risk of GO [29]. However, even in 131-I treatment of Graves' disease severe GO progression, especially in patients without initial GO symptoms, is rare [30]. In one patient after treatment we observed an increase of TRAb, while a reduction of these antibodies in 6 other patients was noticed. Despite the described TRAb increase following radioiodine therapy for Graves disease [31, 32] and in thyroid cancers [33, 34], autonomous thyroid disease [35], as well as nontoxic goitre [36], we did not obtain such results. Long observation time, assessment at only two time points, or advanced patient's age may be of importance for these results.

It should be taken into consideration that 131-I administration, especially in case of very large or substernal goitres, entails a risk of thyroid enlargement. Numerous authors encourage the use of this method, but tend to undermine the significance of the problem. A week after 131-I administration, Bonnema et al. observed thyroid enlargement in 9 out of 23 patients, with increased thyroid volume of more than 5% of the initial value in 4 cases [20]. Following the nontoxic goitre 131-I treatment, thyroid enlargement of more than 5% was described by Nygaard et al. in 9 out of 130 patients, with the median enlargement being 23% (11–60%) [2]. In our work, thyroid enlargement was observed in 2 patients (5.71%) 3 months after the treatment, but it did not exceed 20% of the initial volume. During the treatment, thyroid enlargement by a maximum of 55% was reported in 7 patients (20%). In none of the patients increased dyspnoea, stridor, or pressure sensation in the neck were observed. Eventually, all patients were reported to have their goitres decreased in size. The above results should not discourage 131-I administration, but rather encourage monitoring patients more frequently during and after the treatment.

A complication after low 131-I activity administration, to the best of our knowledge previously never reported, is radiation parotid gland damage. In our work this complication was observed in one case after the third 131-I administration. This patient had previously been suspected of Sjögren's syndrome but had never been fully diagnosed. In our opinion, previous salivary gland damage may increase the risk of radiation damage of the salivary gland even if the patient is administered low 131-I activities.

Conclusions

Fractionated 131-I treatment of large nodular goitres is safe, effective, and, what needs to be emphasised, convenient method of treatment for the patient. The efficacy of the therapy with a reduction of 43% will not differ from high, single-dose treatment. The therapy is a good alternative to surgery and may be successfully conducted by dose fractionation in every outpatient centre that uses radioisotopes for therapy.

References

1. Baczyk M, Pisarek M, Czeczynski R et al. Therapy of large multinodular goitre using repeated doses of radioiodine. *Nucl Med Commun* 2009; 30: 226–231.
2. Nygaard B, Hegedus L, Ulriksen P et al. Radioiodine therapy for multinodular toxic goiter. *Arch Intern Med* 1999; 159: 1364–1368.
3. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. *Endocr Rev* 2003; 24: 102–132.
4. Kaniuka S, Lass P, Sworzczak K. Radioiodine — an attractive alternative to surgery in large non-toxic multinodular goitres. *Nucl Med Rev Cent East Eur* 2009; 12: 23–29.
5. Bonnema SJ, Hegedus L. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. *Curr Opin Endocrinol Diabetes Obes* 2009; 16: 379–384.
6. Fast S, Nielsen VE, Grupe P et al. Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. *J Clin Endocrinol Metab* 2012; 97: 2653–2660.
7. Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes; practical considerations in therapy and protection. *AJR Am J Roentgenol* 1948; 59: 260–281.
8. Brunn J, Block U, Ruf G et al. Volumetric-Analysis of Thyroid Lobes by Real-Time Ultrasound. *Dtsch Med Wochenschr* 1981; 106: 1338–1340.
9. Kaniuka-Jakubowska S, Piskunowicz M, Zapasnik A et al. US not bright but right method of thyroid volume estimation even in large and substernal extended goitres. Comparison of US and three methods of CT thyroid evaluation — prospective study. *Clin Endocrinol (Oxf)* 2014; doi: 10.1111/cen.12629 2014.
10. Berghout A, Wiersinga WM, Drexhage HA et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. *Lancet* 1990; 336: 193–197.
11. Berghout A, Wiersinga WM, Smits NJ et al. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. *Am J Med* 1990; 89: 602–608.
12. Nygaard B, Hegedus L, Gervil M et al. Radioiodine treatment of multinodular non-toxic goiter. *BMJ* 1993; 307: 828–832.
13. Pisarek M, Baczyk M, Gryczynska M et al. The treatment of multinodular large non-toxic goiter using repeated doses of radioiodine (preliminary report). *Endokrynol Pol* 2007; 58: 18–26.
14. Sia-Atanacio AY, Mercado-Asis LB. Radioactive Iodine Therapy is Effective in Diffuse and Nodular Non-toxic Goiter. *Philippine Journal of Internal Medicine* 2011; 49: 70–73.
15. Nygaard B, Hegedus L, Gervil M et al. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. *J Intern Med* 1995; 238: 491–497.
16. Nygaard B, Hegedus L, Nielsen KG et al. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. *Clin Endocrinol (Oxf)* 1999; 50: 197–202.
17. Nygaard B, Farber J, Veje A et al. Thyroid volume and function after 131I treatment of diffuse non-toxic goitre. *Clin Endocrinol (Oxf)* 1997; 46(4): 493–496.
18. Hegedus L, Bennedbaek FN. Radioiodine for non-toxic diffuse goiter. *Lancet* 1997; 350: 409–410.
19. Beckers C. Regulations and policies on radioiodine 131I therapy in Europe. *Thyroid* 1997; 7: 221–224.
20. Bonnema SJ, Bertelsen H, Mortensen J et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. *J Clin Endocrinol Metab* 1999; 84: 3636–3641.
21. Bonnema SJ, Nielsen VE, Hegedus L. Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre. *Eur J Endocrinol* 2004; 150: 439–445.

22. Wesche MF, Tiel V, Lips P et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. *J Clin Endocrinol Metab* 2001; 86: 998–1005.
23. Verelst J, Bonnyns M, Clinoer D. Radioiodine therapy in voluminous multinodular non-toxic goitre. *Acta Endocrinol (Copenh)* 1990; 122: 417–421.
24. Le Moli R, Wesche MF, Tiel-Van Buul MM et al. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. *Clin Endocrinol (Oxf)* 1999; 50: 783–789.
25. Jarlov AE, Hegedus L, Kristensen LO et al. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? *Clin Endocrinol (Oxf)* 1995; 43: 325–329.
26. Wesche MF, Buul MM, Smits NJ et al. Reduction in goiter size by ¹³¹I therapy in patients with non-toxic multinodular goiter. *Eur J Endocrinol* 1995; 132: 86–87.
27. Nygaard B, Knudsen JH, Hegedus L et al. Thyrotropin receptor antibodies and Graves' disease, a side-effect of ¹³¹I treatment in patients with nontoxic goiter. *J Clin Endocrinol Metab* 1997; 82: 2926–2930.
28. Nygaard B, Metcalfe RA, Phipps J et al. Graves' disease and thyroid associated ophthalmopathy triggered by ¹³¹I treatment of non-toxic goiter. *J Endocrinol Invest* 1999; 22: 481–485.
29. Sawicka-Gutaj N, Gutaj P, Sowinski J et al. Influence of cigarette smoking on thyroid gland — an update. *Endokrynol Pol* 2014; 65: 54–62.
30. Krol A, Koehler A, Nowak M et al. Radioactive iodine (RAI) treatment of hyperthyroidism is safe in patients with Graves' orbitopathy — a prospective study. *Endokrynol Pol* 2014; 65: 40–45.
31. Chiappori A, Villalta D, Bossert I et al. Thyrotropin receptor autoantibody measurement following radiometabolic treatment of hyperthyroidism: comparison between different methods. *J Endocrinol Invest* 2010; 33: 197–201.
32. Laurberg P, Wallin G, Tallstedt L et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. *Eur J Endocrinol* 2008; 158: 69–75.
33. Giovansili L, Cayrolle G, Belange G et al. Graves' ophthalmopathy after total thyroidectomy for papillary carcinoma. *Ann Endocrinol (Paris)* 2011; 72: 42–44.
34. Berg G, Andersson T, Sjodell L et al. Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid. *Thyroid* 2005; 15: 1389–1394.
35. Schmidt M, Gorbauch E, Dietlein M et al. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. *Thyroid* 2006; 16: 281–288.
36. Dunkelmann S, Wolf R, Koch A et al. Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. *Eur J Nucl Med Mol Imaging* 2004; 31: 1428–1434.